Consistent with its strategy to expand in the growing
non-invasive prenatal testing (NIPT) market in Europe, leading life
) has entered into three separate partnership agreements. The
company announced that, per the terms of the respective deals,
Biomnis, Genoma, and the Center for Human Genetics and Laboratory
Diagnostics Martinsrieduse will use Illumina's HiSeq 2500 and
consumables in order to develop and perform NIPT in several
locations of Europe.
Illumina strongly believes such strategic partnerships will act
as a major breakthrough in establishing it as a forerunner in
reproductive and genetic health solutions worldwide. This will also
strengthen its position as a valued partner for NGS-based testing
across a broad range of clinical applications.
Through Biomnis, a provider of medical laboratory testing
services, NIPT will now be available in France. Biomnis believes,
with the access of Illumina's whole genome sequencing, it will be
able to deliver its tests with the highest level of accuracy.
On the other hand, molecular genetics laboratory Genoma and
Munich-based Center for Human Genetics and Laboratory Diagnostics
Martinsrieduse will offer NIPT in Italy and Germany respectively.
Genoma expects that access to NIPT through its network with the use
of Illumina's technology will help it improve its service and
offerings for patients and healthcare providers.
According to the Center for Human Genetics and Laboratory
Diagnostics Martinsrieduse, formation of this Prenatalis Consortium
will help it set standards and further develop applications of NIPT
in cooperation with major prenatal centers in Germany.
Illumina enjoys a strong position in the life sciences market
and we are impressed with the strong momentum of its sequencing
instruments, sequencing consumables as well as Sample Prep.
Illumina is currently focusing on worldwide sales expansion to
drive growth. Apart from North America, Illumina markets and
distributes its products directly to customers in Europe, Latin
America and the Asia-Pacific region (APAC) either through its
direct selling force or through distributors that specialize in
life science products.
In the last reported quarter, globally, demand for its products
remained strong. Shipments in the Americas grew 24% year over year,
while Europe witnessed a 32% increase.With the impending launch of
a number of new products in 2014, Illumina expects to further
increase its sales and distribution resource in these
The stock currently bears a Zacks Rank #3 (Hold).
Other Stocks to Consider
Investors interested in the biomedical sector can consider
ANI Pharmaceuticals, Inc.
Biogen Idec Inc.
). All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ILLUMINA INC (ILMN): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
To read this article on Zacks.com click here.